Developer docs
API playgroundTry for free, no card

Search company profiles

IamFluidics

Full company profile

uuid00039oh

Namestring
IamFluidics
Legal namestring
IamFluidics B.V.
Websiteurl
iamfluidics.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

IamFluidics B.V. is a Netherlands-based deep-technology company that commercializes IN-AIR MICROFLUIDICS™, a patented chip-free microencapsulation platform invented in the Physics of Fluids group at the University of Twente. Founded in 2018 as a spin-off by Dr. Tom Kamperman and Dr. Claas Willem Visser, the company's core method uses micrometer-sized liquid jets in mid-air to generate monodisperse microparticles, microcapsules, and microfibers with sizes from 30 µm to 3 mm at a coefficient of variation below 5%. The platform is positioned to combine microfluidic-level precision with industrial throughput (claimed at up to 1,000x faster than chip-based microfluidics) while operating with low shear and without toxic solvents, which the company states is gentle enough for live stem cells, probiotics, peptides, and oxidation-sensitive APIs. Manufacturing is conducted under ISO 9001:2015 certification (Kiwa) with ISO 13485 compliance at the pilot facility.

The company operates a platform-plus-products business model serving pharmaceutical, biotech, cell therapy, nutraceutical, and cosmetics customers. Product lines include DMC Dissolvable Microcarriers (alginate-based microcarriers coated with Rousselot collagen that fully dissolve in EDTA + TrypLE within 15 minutes, enabling claimed >90% cell recovery versus ~50% with conventional microcarriers), PDLLA microparticles (40 µm and 70 µm) for long-acting injectables, and the SlimBeads™ brand of plastic-free vegan nutraceutical capsules for weight management. Revenue is also generated through Microencapsulation as a Service engagements structured in four stages — feasibility assessment (€10,000 entry), design and optimization, functional validation, and commercialization via contract manufacturing or technology transfer — plus equipment sales of IamFluidics benchtop instrumentation to research institutions.

IamFluidics has disclosed funding of approximately €6.3 million in equity (€1M seed from Innovation Industries in December 2018 and €4M Series A in September 2022 led by Joost van Neck with Innovation Industries), supplemented by a €1.3M REACT-EU grant in March 2023, multiple EFRO and OP Oost subsidies, and an undisclosed Oost NL/Innovation Industries round in October 2024. Named customers and partners include Erasmus MC, Scinus Cell Expansion, Fraunhofer ISC TLZ-RT and IBMT, Corbion, University of Twente, and Rousselot (Darling Ingredients) as a co-development and co-distribution partner. The company established direct commercial leadership in Switzerland (CCO Pavel Abdulkin) and Boston (Strategic Business Partner Richard Gray) in October 2025, signaling a transition from technology-development phase to enterprise commercial scaling.

Short descriptiontext

IamFluidics, a University of Twente spin-off, commercializes IN-AIR MICROFLUIDICS™, a patented chip-free jetting platform producing monodisperse microparticles for pharmaceutical, cell therapy, nutraceutical, and cosmetics applications with industrial-scale throughput.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEnschede, Netherlands
HQ citystring
Enschede
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in-air microfluidics, microencapsulation services, dissolvable microcarriers, controlled release injectables, bioresorbable microparticles
Industry1 code
PRIMARYHLAGAHAJ
Crystallization, Particle Engineering & Micronization Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
Product category
Microencapsulation Materials & Services
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Product Sales — Dissolvable Microcarriers
TypeHardware Sales
Description

Sale of research-grade Dissolvable Microcarriers (1g and 10g packs) via the microparticles.shop e-commerce platform. GMP-compliant versions available by direct inquiry. Revenue from unit product sales to research institutions, biotech companies, and cell therapy developers.

iamfluidics.com
2Microencapsulation as a Service (合同开发和制造服务)
TypeProfessional Services
Description

Four-stage service offering: Feasibility Assessment (€10,000), Design & Optimization, Functional Validation, and Commercialization (contract manufacturing or technology transfer). Enables customers to access the IN-AIR MICROFLUIDICS™ platform without capital investment. Typical batch sizes range from 0–1 kg (R&D lab) to 1–100 kg (industrial pilot).

iamfluidics.com
3Equipment Sales — IamFluidics Setup
TypeHardware Sales
Description

Sale of IamFluidics benchtop setups (IN-AIR MICROFLUIDICS™ instrumentation) to research institutions and industrial partners. The first IamFluidics setup was sold to the Thermal and Fluid Engineering department at the University of Twente for fundamental research and process development.

iamfluidics.com
4Custom Microparticle Development & Co-Development
TypeLicensing Royalties
Description

Custom bead design and formulation development partnerships with industry clients. Interdisciplinary scientific team engineers microparticles tailored to specific polymers, APIs, biologics, or cells of interest. Can lead to co-branded or exclusive product arrangements.

iamfluidics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details4 tiers
1Feasibility Study — Entry-level microencapsulation service engagement
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

€10,000 per feasibility study to demonstrate material compatibility with IN-AIR MICROFLUIDICS™ technology. Covers Stage 1 of the microencapsulation service pipeline.

iamfluidics.com
2Design & Optimization — Tailored microparticle development
ModelOtherBilling cadenceMulti-year contract
Notes

Custom pricing based on project scope, complexity, and required functionalities. Follows feasibility stage.

iamfluidics.com
3Commercialization — Scale-up and manufacturing or technology transfer
ModelOtherBilling cadenceMulti-year contract
Notes

Contract manufacturing or technology transfer agreements, priced at project/contract level. Typical pilot-scale batches: 1–100 kg.

iamfluidics.com
4Research-Grade Dissolvable Microcarriers — 1g and 10g packs
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Available for purchase via microparticles.shop. No public pricing listed; quote-based purchasing.

iamfluidics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1IN-AIR MICROFLUIDICS™
Description

Patented chip-free, high-throughput microencapsulation technology that combines microfluidic precision with industrial scalability using micrometer-sized liquid jets in mid-air to create uniform microparticles, microcapsules, and microfibers from 30µm to 3mm.

iamfluidics.com
+3 more records
Core offering1 text field

IamFluidics develops and operates a proprietary IN-AIR MICROFLUIDICS™ chip-free microencapsulation platform that produces monodisperse microparticles (30 µm to 3 mm) at industrial throughput. The company sells bioresorbable polymer microparticles (PDLLA) and alginate-based Dissolvable Microcarriers for cell culture, and offers contract microencapsulation services spanning feasibility studies, custom development, scale-up, and technology transfer.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • ≥1×10⁹ Mesenchymal Stem Cells produced within 14 days in a scalable bioreactor process
+7 more records
Product overview1 text field

IamFluidics operates a platform-plus-products business model centered on its proprietary IN-AIR MICROFLUIDICS™ technology, a chip-free microencapsulation platform that combines microfluidic-level precision with industrial-scale throughput (up to 1,000x faster than conventional chip-based microfluidics). The commercial product portfolio includes DMC Dissolvable Microcarriers (developed with Rousselot, available in 1g and 10g research-grade packs) for scalable adherent cell culture in bioreactors, PDLLA microparticles (40 µm and 70 µm) for controlled injectables, and SlimBeads™ for nutraceutical weight management applications. The company complements its product sales with microencapsulation-as-a-service offerings spanning feasibility studies, co-development, scale-up, and technology transfer, delivered through ISO 9001:2015 certified R&D and pilot facilities.

Product and service8 records
1DMC Dissolvable Microcarriers - 1g
CategoryCell Culture Substrates
Description

Alginate-based microcarriers coated with denatured collagen (gelatin from Rousselot) for small-scale adherent cell culture studies and process development. Fully dissolves in EDTA + TrypLE within 15 minutes, enabling over 90% cell recovery.

2DMC Dissolvable Microcarriers - 10g
CategoryCell Culture Substrates
Description

Alginate-based microcarriers coated with denatured collagen (gelatin from Rousselot) for larger-scale adherent cell culture and bioreactor applications. Dissolves fully in standard reagents in 15 minutes for high-yield cell harvesting.

3PDLLA microparticles (40 µm)
CategoryDrug Delivery Microparticles
Description

Bioresorbable poly-DL-lactic acid microparticles at 40 µm diameter for controlled injectables and drug delivery applications. Tight size distribution (CV below 5%) supports consistent drug release profiles.

4PDLLA microparticles (70 µm)
CategoryDrug Delivery Microparticles
Description

Bioresorbable poly-DL-lactic acid microparticles at 70 µm diameter for controlled injectables and drug delivery applications. Tight size distribution enables predictable release kinetics.

5SlimBeads™
CategoryNutraceutical Microcapsules
Description

Plastic-free, vegan, biodegradable alginate-based nutraceutical microcapsules for weight management via ileal brake activation and endogenous GLP-1 release. Provides enteric protection with tunable intestinal release of actives.

6IN-AIR MICROFLUIDICS™ Technology Platform
CategoryMicroencapsulation Technology
Description

Patented chip-free microencapsulation platform using micrometer-sized liquid jets in mid-air to produce uniform microparticles, microcapsules, and microfibers from 30 µm to 3 mm. Combines microfluidic-level precision (CV below 5%) with industrial throughput up to 1000x faster than chip-based microfluidics; solvent-free and gentle enough for live cells, peptides, and probiotics.

7Microencapsulation as a Service
CategoryContract Manufacturing Services
Description

Contract microencapsulation services covering feasibility assessment, design and optimization, functional validation, and commercialization (contract manufacturing or technology transfer). Delivered through ISO 9001:2015 certified R&D labs (ISO-7 cleanroom, ML1 facility) for 0–1 kg batches and ISO 13485-compliant industrial pilot facility for 1–100 kg batches.

8IamFluidics Benchtop Equipment Setup
CategoryMicroencapsulation Equipment
Description

Lab-scale, pilot-scale, and multi-ton IN-AIR MICROFLUIDICS™ benchtop instrumentation sold to research institutions and industrial partners for in-house microencapsulation development and production.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-12
Description

Co-development and co-commercialization of Dissolvable Microcarriers (DMC) for adherent cell culture. IamFluidics contributes IN-AIR MICROFLUIDICS™ production technology; Rousselot provides ultra-pure, endotoxin-controlled denatured collagen (gelatin) with full ISO 22442-2 traceability and viral inactivation validation. Product co-branded and distributed via Rousselot's biomedical commercial network. Rousselot has 130+ years of collagen expertise.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Joint validation of Dissolvable Microcarriers in the Osilaris™ bioreactor for scalable MSC expansion. Published application note demonstrating ≥1×10⁹ cells in 14 days. Scinus provides bioreactor platform; IamFluidics provides cell culture substrate. Partnership demonstrates DMC compatibility with industry-standard suspension bioreactor workflows.

3Fraunhofer ISC TLZ-RT and IBMT
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Independent validation of Dissolvable Microcarrier performance. Conducted flow cytometry analysis confirming MSC phenotype preservation (≥95% CD73/CD90/CD105, ≤2% CD14/CD19/CD34/CD45) and trilineage differentiation potential post-harvest. Provides regulatory-grade validation data for customer adoption.

iamfluidics.com
Strategic tierSupportingTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-09-16
Description

University of Twente's startup incubator that facilitated IamFluidics' spin-off formation and early startup activities. Provides ongoing ecosystem networking support, including introductions to investors and partners. Supported the 2022 investment announcement communications.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Collaboration on controlled-release microparticle development using PLGA polymers for pharmaceutical applications. Corbion provides PLA and PLGA polymer expertise; IamFluidics provides IN-AIR MICROFLUIDICS™ encapsulation platform. Case studies published on curcumin solubilization and long-acting release demonstrating 4+ weeks sustained delivery.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Research collaboration led by Dr. Meinou Corstens and Prof. Karin Schroën on SlimBeads™ nutraceutical product. WUR conducted clinical research demonstrating that oil-containing microcapsules can reduce food intake without changing product appearance or taste (ileal brake activation). REACT-EU funded joint project for plastic-free vegan weight management microcapsules.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2018-09-20
Description

EFRO-funded consortium for in-air microfluidics upscaling project. Aquamarijn (Zutphen) and Bether Encapsulates (Groningen) collaborated with IamFluidics and University of Twente to develop monodisperse microdroplet production for industrial applications.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Spin-off origin and ongoing academic partner. IN-AIR MICROFLUIDICS™ technology invented in the Physics of Fluids group (Prof. Detlef Lohse, Dr. Claas Willem Visser) and Developmental BioEngineering group (Prof. Marcel Karperien, Dr. Tom Kamperman). Ongoing collaborations with Fluid Mechanics for Functional Materials, Leijten Laboratory, and Vascularization Lab at University of Twente for next-generation microbeads and tissue engineering applications.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Microfluidics company specializing in single-cell analysis, cell manipulation, and picodroplet-based workflows used in biologics discovery and cell therapy development. Comparable microfluidic platform serving overlapping biologics/pharma customers.

TypeDirect peer
Description

Provider of microfluidic flow control instruments and droplet generation systems used in life sciences research and particle production. Directly comparable on the microfluidics instrumentation and fluid handling side.

TypeEmerging player
Description

Microfluidics company focused on miniaturized cell processing and washing for cell therapy and immuno-oncology workflows using laminar flow technologies. Overlaps in microfluidic cell processing for cell therapy customers.

TypeDirect peer
Description

Manufacturer of microfluidic systems for nano- and microparticle production, including flow chemistry and droplet generation platforms. Closely aligned with IamFluidics' equipment side; Richard Gray was also previously Commercial Director at Syrris.

TypeBroad incumbent
Description

Global CDMO with extensive particle engineering and microencapsulation services for pharma (including former Bend Research capability). Overlaps with IamFluidics in pharma microencapsulation services and bioresorbable polymer particle production.

TypeBroad incumbent
Description

Major global CDMO offering softgel, controlled-release, and particle-based drug delivery services including PLGA-based long-acting injectables. Comparable on pharma drug delivery CDMO offerings, though much broader portfolio.

TypeDirect peer
Description

Microencapsulation specialist using microfluidic flow focusing to generate monodisperse droplets and particles, including alginate hydrogel microparticles. Highly comparable to IamFluidics' core offering; notably, IamFluidics' new CCO Pavel Abdulkin was previously Particle Works' CEO.

TypeBroad incumbent
Description

Specialty chemicals company with a Health Care division producing RESOMER bioresorbable PLA/PLGA polymers used in long-acting injectables and offering CDMO services for parenteral drug delivery. Comparable in bioresorbable polymer particle production for pharma.

9Dolomite Microfluidics
TypeDirect peer
Description

Designs and manufactures microfluidic chips, instruments, and complete systems for particle generation, droplet microfluidics, and lab-on-a-chip research. Direct comparable in microfluidics equipment; IamFluidics' Strategic Business Partner Richard Gray was previously Commercial Director there.

10Blacktrace Holdings
TypeBroad incumbent
Description

Parent company of Dolomite Microfluidics and Syrris, providing a portfolio of microfluidic and particle generation technologies across multiple applications. Broader incumbent operating across the same microfluidic particle-production space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IamFluidics

Microencapsulation Materials & Servicesiamfluidics.com

IamFluidics, a University of Twente spin-off, commercializes IN-AIR MICROFLUIDICS™, a patented chip-free jetting platform producing monodisperse microparticles for pharmaceutical, cell therapy, nutraceutical, and cosmetics applications with industrial-scale throughput.

What IamFluidics does

IamFluidics B.V. is a Netherlands-based deep-technology company that commercializes IN-AIR MICROFLUIDICS™, a patented chip-free microencapsulation platform invented in the Physics of Fluids group at the University of Twente. Founded in 2018 as a spin-off by Dr. Tom Kamperman and Dr. Claas Willem Visser, the company's core method uses micrometer-sized liquid jets in mid-air to generate monodisperse microparticles, microcapsules, and microfibers with sizes from 30 µm to 3 mm at a coefficient of variation below 5%. The platform is positioned to combine microfluidic-level precision with industrial throughput (claimed at up to 1,000x faster than chip-based microfluidics) while operating with low shear and without toxic solvents, which the company states is gentle enough for live stem cells, probiotics, peptides, and oxidation-sensitive APIs. Manufacturing is conducted under ISO 9001:2015 certification (Kiwa) with ISO 13485 compliance at the pilot facility.

The company operates a platform-plus-products business model serving pharmaceutical, biotech, cell therapy, nutraceutical, and cosmetics customers. Product lines include DMC Dissolvable Microcarriers (alginate-based microcarriers coated with Rousselot collagen that fully dissolve in EDTA + TrypLE within 15 minutes, enabling claimed >90% cell recovery versus ~50% with conventional microcarriers), PDLLA microparticles (40 µm and 70 µm) for long-acting injectables, and the SlimBeads™ brand of plastic-free vegan nutraceutical capsules for weight management. Revenue is also generated through Microencapsulation as a Service engagements structured in four stages — feasibility assessment (€10,000 entry), design and optimization, functional validation, and commercialization via contract manufacturing or technology transfer — plus equipment sales of IamFluidics benchtop instrumentation to research institutions.

IamFluidics has disclosed funding of approximately €6.3 million in equity (€1M seed from Innovation Industries in December 2018 and €4M Series A in September 2022 led by Joost van Neck with Innovation Industries), supplemented by a €1.3M REACT-EU grant in March 2023, multiple EFRO and OP Oost subsidies, and an undisclosed Oost NL/Innovation Industries round in October 2024. Named customers and partners include Erasmus MC, Scinus Cell Expansion, Fraunhofer ISC TLZ-RT and IBMT, Corbion, University of Twente, and Rousselot (Darling Ingredients) as a co-development and co-distribution partner. The company established direct commercial leadership in Switzerland (CCO Pavel Abdulkin) and Boston (Strategic Business Partner Richard Gray) in October 2025, signaling a transition from technology-development phase to enterprise commercial scaling.

IamFluidics firmographics

Firmographics
Name
IamFluidics
Legal name
IamFluidics B.V.
Website
https://iamfluidics.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
IamFluidics, a University of Twente spin-off, commercializes IN-AIR MICROFLUIDICS™, a patented chip-free jetting platform producing monodisperse microparticles for pharmaceutical, cell therapy, nutraceutical, and cosmetics applications with industrial-scale throughput.
Ownership category
akta.pro rank

IamFluidics industry classification

Industry
Product category
Microencapsulation Materials & Services
akta.pro industry
PRIMARYHLAGAHAJ
Crystallization, Particle Engineering & Micronization Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • In-air microfluidics
  • Microencapsulation services
  • Dissolvable microcarriers
  • Controlled release injectables
  • Bioresorbable microparticles

Where IamFluidics is headquartered

Location

Headquarters

HQ city
Enschede
HQ country
Netherlands
HQ region
Europe

Offices4 records

Markets served

IamFluidics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Product Sales — Dissolvable Microcarriers: Sale of research-grade Dissolvable Microcarriers (1g and 10g packs) via the microparticles.shop e-commerce platform. GMP-compliant versions available by direct inquiry. Revenue from unit product sales to research institutions, biotech companies, and cell therapy developers.
  2. Microencapsulation as a Service (合同开发和制造服务): Four-stage service offering: Feasibility Assessment (€10,000), Design & Optimization, Functional Validation, and Commercialization (contract manufacturing or technology transfer). Enables customers to access the IN-AIR MICROFLUIDICS™ platform without capital investment. Typical batch sizes range from 0–1 kg (R&D lab) to 1–100 kg (industrial pilot).
  3. Equipment Sales — IamFluidics Setup: Sale of IamFluidics benchtop setups (IN-AIR MICROFLUIDICS™ instrumentation) to research institutions and industrial partners. The first IamFluidics setup was sold to the Thermal and Fluid Engineering department at the University of Twente for fundamental research and process development.
  4. Custom Microparticle Development & Co-Development: Custom bead design and formulation development partnerships with industry clients. Interdisciplinary scientific team engineers microparticles tailored to specific polymers, APIs, biologics, or cells of interest. Can lead to co-branded or exclusive product arrangements.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goFeasibility Study — Entry-level microencapsulation service engagement
OtherMulti-year contractDesign & Optimization — Tailored microparticle development
OtherMulti-year contractCommercialization — Scale-up and manufacturing or technology transfer
Unit PricingPay-as-you-goResearch-Grade Dissolvable Microcarriers — 1g and 10g packs

Go-to-market motion4 records

Distribution channels6 records

Marketing channels6 records

IamFluidics product offering

Product offering

Core offering

IamFluidics develops and operates a proprietary IN-AIR MICROFLUIDICS™ chip-free microencapsulation platform that produces monodisperse microparticles (30 µm to 3 mm) at industrial throughput. The company sells bioresorbable polymer microparticles (PDLLA) and alginate-based Dissolvable Microcarriers for cell culture, and offers contract microencapsulation services spanning feasibility studies, custom development, scale-up, and technology transfer.

Product overview

IamFluidics operates a platform-plus-products business model centered on its proprietary IN-AIR MICROFLUIDICS™ technology, a chip-free microencapsulation platform that combines microfluidic-level precision with industrial-scale throughput (up to 1,000x faster than conventional chip-based microfluidics). The commercial product portfolio includes DMC Dissolvable Microcarriers (developed with Rousselot, available in 1g and 10g research-grade packs) for scalable adherent cell culture in bioreactors, PDLLA microparticles (40 µm and 70 µm) for controlled injectables, and SlimBeads™ for nutraceutical weight management applications. The company complements its product sales with microencapsulation-as-a-service offerings spanning feasibility studies, co-development, scale-up, and technology transfer, delivered through ISO 9001:2015 certified R&D and pilot facilities.

Differentiator

Problem solved

Functional benefit

Brands

  • IN-AIR MICROFLUIDICS™: Patented chip-free, high-throughput microencapsulation technology that combines microfluidic precision with industrial scalability using micrometer-sized liquid jets in mid-air to create uniform microparticles, microcapsules, and microfibers from 30µm to 3mm.
  • SlimBeads™
  • DMC Dissolvable Microcarriers
  • ApiBead™

Products and services

  • DMC Dissolvable Microcarriers - 1g Alginate-based microcarriers coated with denatured collagen (gelatin from Rousselot) for small-scale adherent cell culture studies and process development. Fully dissolves in EDTA + TrypLE within 15 minutes, enabling over 90% cell recovery.
  • DMC Dissolvable Microcarriers - 10g Alginate-based microcarriers coated with denatured collagen (gelatin from Rousselot) for larger-scale adherent cell culture and bioreactor applications. Dissolves fully in standard reagents in 15 minutes for high-yield cell harvesting.
  • PDLLA microparticles (40 µm) Bioresorbable poly-DL-lactic acid microparticles at 40 µm diameter for controlled injectables and drug delivery applications. Tight size distribution (CV below 5%) supports consistent drug release profiles.
  • PDLLA microparticles (70 µm) Bioresorbable poly-DL-lactic acid microparticles at 70 µm diameter for controlled injectables and drug delivery applications. Tight size distribution enables predictable release kinetics.
  • SlimBeads™ Plastic-free, vegan, biodegradable alginate-based nutraceutical microcapsules for weight management via ileal brake activation and endogenous GLP-1 release. Provides enteric protection with tunable intestinal release of actives.
  • IN-AIR MICROFLUIDICS™ Technology Platform Patented chip-free microencapsulation platform using micrometer-sized liquid jets in mid-air to produce uniform microparticles, microcapsules, and microfibers from 30 µm to 3 mm. Combines microfluidic-level precision (CV below 5%) with industrial throughput up to 1000x faster than chip-based microfluidics; solvent-free and gentle enough for live cells, peptides, and probiotics.
  • Microencapsulation as a Service Contract microencapsulation services covering feasibility assessment, design and optimization, functional validation, and commercialization (contract manufacturing or technology transfer). Delivered through ISO 9001:2015 certified R&D labs (ISO-7 cleanroom, ML1 facility) for 0–1 kg batches and ISO 13485-compliant industrial pilot facility for 1–100 kg batches.
  • IamFluidics Benchtop Equipment Setup Lab-scale, pilot-scale, and multi-ton IN-AIR MICROFLUIDICS™ benchtop instrumentation sold to research institutions and industrial partners for in-house microencapsulation development and production.

Quantifiable outcome

  • ≥1×10⁹ Mesenchymal Stem Cells produced within 14 days in a scalable bioreactor process
  • +7 more outcomes

Companies that use IamFluidics

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles5 records

IamFluidics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

IamFluidics partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and supporting.

  • Rousselot (Darling Ingredients)coreStrategic or Co-development Partner · 12 November 2024Co-development and co-commercialization of Dissolvable Microcarriers (DMC) for adherent cell culture. IamFluidics contributes IN-AIR MICROFLUIDICS™ production technology; Rousselot provides ultra-pure, endotoxin-controlled denatured collagen (gelatin) with full ISO 22442-2 traceability and viral inactivation validation. Product co-branded and distributed via Rousselot's biomedical commercial network. Rousselot has 130+ years of collagen expertise.
  • Scinus Cell ExpansioncoreStrategic or Co-development Partner · 1 January 2024Joint validation of Dissolvable Microcarriers in the Osilaris™ bioreactor for scalable MSC expansion. Published application note demonstrating ≥1×10⁹ cells in 14 days. Scinus provides bioreactor platform; IamFluidics provides cell culture substrate. Partnership demonstrates DMC compatibility with industry-standard suspension bioreactor workflows.
  • Fraunhofer ISC TLZ-RT and IBMTsupportingStrategic or Co-development Partner · 1 January 2024Independent validation of Dissolvable Microcarrier performance. Conducted flow cytometry analysis confirming MSC phenotype preservation (≥95% CD73/CD90/CD105, ≤2% CD14/CD19/CD34/CD45) and trilineage differentiation potential post-harvest. Provides regulatory-grade validation data for customer adoption.
  • Novel-TsupportingChannel Partner/ Reseller/ Distributor · 16 September 2022University of Twente's startup incubator that facilitated IamFluidics' spin-off formation and early startup activities. Provides ongoing ecosystem networking support, including introductions to investors and partners. Supported the 2022 investment announcement communications.
  • CorbioncoreStrategic or Co-development Partner · 1 January 2021Collaboration on controlled-release microparticle development using PLGA polymers for pharmaceutical applications. Corbion provides PLA and PLGA polymer expertise; IamFluidics provides IN-AIR MICROFLUIDICS™ encapsulation platform. Case studies published on curcumin solubilization and long-acting release demonstrating 4+ weeks sustained delivery.
  • Wageningen University & Research (WUR)coreStrategic or Co-development Partner · 1 January 2020Research collaboration led by Dr. Meinou Corstens and Prof. Karin Schroën on SlimBeads™ nutraceutical product. WUR conducted clinical research demonstrating that oil-containing microcapsules can reduce food intake without changing product appearance or taste (ileal brake activation). REACT-EU funded joint project for plastic-free vegan weight management microcapsules.
  • Aquamarijn Microfiltration B.V., Bether Encapsulates B.V., University of Twente (Consortium)supportingStrategic or Co-development Partner · 20 September 2018EFRO-funded consortium for in-air microfluidics upscaling project. Aquamarijn (Zutphen) and Bether Encapsulates (Groningen) collaborated with IamFluidics and University of Twente to develop monodisperse microdroplet production for industrial applications.
  • University of TwentecoreStrategic or Co-development Partner · 1 January 2018Spin-off origin and ongoing academic partner. IN-AIR MICROFLUIDICS™ technology invented in the Physics of Fluids group (Prof. Detlef Lohse, Dr. Claas Willem Visser) and Developmental BioEngineering group (Prof. Marcel Karperien, Dr. Tom Kamperman). Ongoing collaborations with Fluid Mechanics for Functional Materials, Leijten Laboratory, and Vascularization Lab at University of Twente for next-generation microbeads and tissue engineering applications.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

IamFluidics competitors and assessment

Company assessment

Direct peers

  • Sphere Fluidics: Microfluidics company specializing in single-cell analysis, cell manipulation, and picodroplet-based workflows used in biologics discovery and cell therapy development. Comparable microfluidic platform serving overlapping biologics/pharma customers.
  • Fluigent: Provider of microfluidic flow control instruments and droplet generation systems used in life sciences research and particle production. Directly comparable on the microfluidics instrumentation and fluid handling side.
  • Syrris: Manufacturer of microfluidic systems for nano- and microparticle production, including flow chemistry and droplet generation platforms. Closely aligned with IamFluidics' equipment side; Richard Gray was also previously Commercial Director at Syrris.
  • Particle Works: Microencapsulation specialist using microfluidic flow focusing to generate monodisperse droplets and particles, including alginate hydrogel microparticles. Highly comparable to IamFluidics' core offering; notably, IamFluidics' new CCO Pavel Abdulkin was previously Particle Works' CEO.
  • Dolomite Microfluidics: Designs and manufactures microfluidic chips, instruments, and complete systems for particle generation, droplet microfluidics, and lab-on-a-chip research. Direct comparable in microfluidics equipment; IamFluidics' Strategic Business Partner Richard Gray was previously Commercial Director there.

Emerging players

  • Curiox Biosystems: Microfluidics company focused on miniaturized cell processing and washing for cell therapy and immuno-oncology workflows using laminar flow technologies. Overlaps in microfluidic cell processing for cell therapy customers.

Broad incumbents

  • Lonza: Global CDMO with extensive particle engineering and microencapsulation services for pharma (including former Bend Research capability). Overlaps with IamFluidics in pharma microencapsulation services and bioresorbable polymer particle production.
  • Catalent: Major global CDMO offering softgel, controlled-release, and particle-based drug delivery services including PLGA-based long-acting injectables. Comparable on pharma drug delivery CDMO offerings, though much broader portfolio.
  • Evonik: Specialty chemicals company with a Health Care division producing RESOMER bioresorbable PLA/PLGA polymers used in long-acting injectables and offering CDMO services for parenteral drug delivery. Comparable in bioresorbable polymer particle production for pharma.
  • Blacktrace Holdings: Parent company of Dolomite Microfluidics and Syrris, providing a portfolio of microfluidic and particle generation technologies across multiple applications. Broader incumbent operating across the same microfluidic particle-production space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights4 records

Customer concentration

IamFluidics social profiles

Digital presence

IamFluidics compliance and trust

Trust signal

Compliance2 records

IamFluidics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IamFluidics leadership team

Management profile

Number of profiles

Profiles4 records

IamFluidics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IamFluidics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IamFluidics

What does IamFluidics do?

IamFluidics develops and operates a proprietary IN-AIR MICROFLUIDICS™ chip-free microencapsulation platform that produces monodisperse microparticles (30 µm to 3 mm) at industrial throughput. The company sells bioresorbable polymer microparticles (PDLLA) and alginate-based Dissolvable Microcarriers for cell culture, and offers contract microencapsulation services spanning feasibility studies, custom development, scale-up, and technology transfer.

Is IamFluidics a public or private company?

IamFluidics is a private company. It is classified as venture growth investor backed and is currently operating.

When was IamFluidics founded?

IamFluidics was founded in 2018. It employs 11 to 50 people.

Where is IamFluidics based?

IamFluidics is headquartered in Enschede, Netherlands, in the Europe region.

How does IamFluidics make money?

Four revenue lines are on record. Product Sales — Dissolvable Microcarriers are the primary driver. The others are microencapsulation as a Service (合同开发和制造服务), equipment Sales — IamFluidics Setup and custom Microparticle Development & Co-Development.

Who are IamFluidics's main competitors?

Direct peers on record are Sphere Fluidics, Fluigent, Syrris, Particle Works and Dolomite Microfluidics. Curiox Biosystems is listed as an emerging player. Broad incumbents are Lonza, Catalent, Evonik and Blacktrace Holdings.

Does IamFluidics have an API?

No public API is recorded for IamFluidics.

What industry is IamFluidics in?

IamFluidics's product category is Microencapsulation Materials & Services. Its primary akta.pro industry code is HLAGAHAJ, Crystallization, Particle Engineering & Micronization Services.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Cultivated XPatent Watch: The Cellular Agriculture Filings Worth Knowing AboutNH Foods, Hanwha Solutions, Tufts University, and IamFluidics have filed patents addressing key technical bottlenecks in cellular agriculture, including plant-based meat texture, cultivated meat cost reduction, serum-free growth media, and cell recovery efficiency. These filings target specific challenges such as protein alignment, simplifying culture supplements, replacing fetal bovine serum with microbial lysates, and improving yield through dissolvable microcarriers. The developments signal ongoing industrial efforts to scale production and improve the quality of alternative proteins.vegconomistPatent Watch: The Cellular Agriculture Filings Worth Knowing AboutNH Foods, Hanwha Solutions, Tufts University, and IamFluidics have filed patents addressing key technical bottlenecks in cellular agriculture, including plant-based meat texture, simplified culture media, serum replacement, and cell recovery. These filings target critical cost and scalability issues such as supplement complexity, fetal bovine serum dependency, and yield loss during manufacturing. The developments signal incremental progress toward making cultivated meat and alternative proteins commercially viable at scale.Silicon CanalsDutch-based IamFluidics raises €4M from Joost van Neck, Innovation Industries: Know moreDutch-based IamFluidics has raised €4 million in funding from entrepreneur Joost van Neck via D.H.B. GreenConcepts B.V. and existing investor Innovation Industries. The company plans to use the capital to establish a new head office, build a production facility, hire staff, and accelerate the market launch of its microparticle technology.InnovationindustriesIamFluidics raises multi-million euro investmentIamFluidics announced on 16 September 2022 the closing of a €4 million financing round from entrepreneur Joost van Neck and existing investor Innovation Industries. The funds will fund a new head office, a production facility, team expansion and market introduction of its first products. The company says its microencapsulation technology is up to 1,000x faster than alternatives.IamfluidicsIamFluidics raises multi-million euro investmentIamFluidics has closed a €4 million financing round led by entrepreneur Joost van Neck and existing investor Innovation Industries. The company plans to use the proceeds to establish a new head office, build a production facility, expand its team, and initiate the market introduction of its microencapsulation technology products.